Clinical trials: Clinical Anxiety
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi